Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes

Hidetoshi Nitta, Takayuki Shimose, Yasunori Emi, Takahisa Imamura, Koji Ohnishi, Tetsuya Kusumoto, Manabu Yamamoto, Kengo Fukuzawa, Ikuo Takahashi, Hidefumi Higashi, Akihito Tsuji, Yoshito Akagi, Eiji Oki, Yoshihiko Maehara, Hideo Baba, Study Group of Clinical Cancer (KSCC) ancillary study Kyushu Study Group of Clinical Cancer (KSCC) ancillary study

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 %) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 %, P = 0.002 and 58.8 vs. 86.1 %, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 %) than in those with low tumoral C5aR expression (3.9 %; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.

Original languageEnglish
Article number118
JournalMedical Oncology
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Anaphylatoxin C5a Receptor
Stomach Neoplasms
Blood Vessels
Neoplasms
Liver
Neoplasm Metastasis
Hepatectomy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Nitta, H., Shimose, T., Emi, Y., Imamura, T., Ohnishi, K., Kusumoto, T., ... Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, S. G. O. C. C. KSCC. A. S. (2016). Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Medical Oncology, 33(11), [118]. https://doi.org/10.1007/s12032-016-0834-9

Expression of the anaphylatoxin C5a receptor in gastric cancer : implications for vascular invasion and patient outcomes. / Nitta, Hidetoshi; Shimose, Takayuki; Emi, Yasunori; Imamura, Takahisa; Ohnishi, Koji; Kusumoto, Tetsuya; Yamamoto, Manabu; Fukuzawa, Kengo; Takahashi, Ikuo; Higashi, Hidefumi; Tsuji, Akihito; Akagi, Yoshito; Oki, Eiji; Maehara, Yoshihiko; Baba, Hideo; Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, Study Group of Clinical Cancer (KSCC) ancillary study.

In: Medical Oncology, Vol. 33, No. 11, 118, 01.11.2016.

Research output: Contribution to journalArticle

Nitta, H, Shimose, T, Emi, Y, Imamura, T, Ohnishi, K, Kusumoto, T, Yamamoto, M, Fukuzawa, K, Takahashi, I, Higashi, H, Tsuji, A, Akagi, Y, Oki, E, Maehara, Y, Baba, H & Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, SGOCCKSCCAS 2016, 'Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes', Medical Oncology, vol. 33, no. 11, 118. https://doi.org/10.1007/s12032-016-0834-9
Nitta, Hidetoshi ; Shimose, Takayuki ; Emi, Yasunori ; Imamura, Takahisa ; Ohnishi, Koji ; Kusumoto, Tetsuya ; Yamamoto, Manabu ; Fukuzawa, Kengo ; Takahashi, Ikuo ; Higashi, Hidefumi ; Tsuji, Akihito ; Akagi, Yoshito ; Oki, Eiji ; Maehara, Yoshihiko ; Baba, Hideo ; Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, Study Group of Clinical Cancer (KSCC) ancillary study. / Expression of the anaphylatoxin C5a receptor in gastric cancer : implications for vascular invasion and patient outcomes. In: Medical Oncology. 2016 ; Vol. 33, No. 11.
@article{ba02f8410e1f4a239b0be18d55d99036,
title = "Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes",
abstract = "The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 {\%}) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 {\%}, P = 0.002 and 58.8 vs. 86.1 {\%}, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 {\%}) than in those with low tumoral C5aR expression (3.9 {\%}; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.",
author = "Hidetoshi Nitta and Takayuki Shimose and Yasunori Emi and Takahisa Imamura and Koji Ohnishi and Tetsuya Kusumoto and Manabu Yamamoto and Kengo Fukuzawa and Ikuo Takahashi and Hidefumi Higashi and Akihito Tsuji and Yoshito Akagi and Eiji Oki and Yoshihiko Maehara and Hideo Baba and {Kyushu Study Group of Clinical Cancer (KSCC) ancillary study}, {Study Group of Clinical Cancer (KSCC) ancillary study}",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/s12032-016-0834-9",
language = "English",
volume = "33",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "11",

}

TY - JOUR

T1 - Expression of the anaphylatoxin C5a receptor in gastric cancer

T2 - implications for vascular invasion and patient outcomes

AU - Nitta, Hidetoshi

AU - Shimose, Takayuki

AU - Emi, Yasunori

AU - Imamura, Takahisa

AU - Ohnishi, Koji

AU - Kusumoto, Tetsuya

AU - Yamamoto, Manabu

AU - Fukuzawa, Kengo

AU - Takahashi, Ikuo

AU - Higashi, Hidefumi

AU - Tsuji, Akihito

AU - Akagi, Yoshito

AU - Oki, Eiji

AU - Maehara, Yoshihiko

AU - Baba, Hideo

AU - Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, Study Group of Clinical Cancer (KSCC) ancillary study

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 %) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 %, P = 0.002 and 58.8 vs. 86.1 %, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 %) than in those with low tumoral C5aR expression (3.9 %; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.

AB - The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 %) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 %, P = 0.002 and 58.8 vs. 86.1 %, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 %) than in those with low tumoral C5aR expression (3.9 %; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84989359850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989359850&partnerID=8YFLogxK

U2 - 10.1007/s12032-016-0834-9

DO - 10.1007/s12032-016-0834-9

M3 - Article

C2 - 27688239

AN - SCOPUS:84989359850

VL - 33

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 11

M1 - 118

ER -